GlassScriptPhysician profile
Tania Arous
NPI 1114468360
$1,326.09
in general payments reported to CMS, 2019-2025
9 companies · $688 in 2025
The $688 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $25.48 · 2023: $238 · 2024: $375 · 2025: $688.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,256 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,255.61 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $372.76 | 2024-2025 | Tepezza |
| Lilly USA, LLC | $169.89 | 2024-2025 | Zepbound |
| Intra-Sana Laboratories | $139.14 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Neurocrine Biosciences, INC. | $131.43 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2023 | Lokelma |
| Ascendis Pharma Endocrinology INC | $124.99 | 2025 | Yorvipath |
| Novo Nordisk INC | $124.88 | 2024 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.52 | 2023 | Jardiance |
| Ascensia Diabetes Care US INC. | $25.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tania Arous listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.